A detailed history of Fifth Third Bancorp transactions in Cytokinetics Inc stock. As of the latest transaction made, Fifth Third Bancorp holds 845 shares of CYTK stock, worth $40,281. This represents 0.0% of its overall portfolio holdings.

Number of Shares
845
Previous 587 43.95%
Holding current value
$40,281
Previous $31,000 41.94%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$51.22 - $60.16 $13,214 - $15,521
258 Added 43.95%
845 $44,000
Q2 2024

Jul 22, 2024

SELL
$47.86 - $75.05 $3,302 - $5,178
-69 Reduced 10.52%
587 $31,000
Q1 2024

Apr 23, 2024

BUY
$63.75 - $108.06 $20,272 - $34,363
318 Added 94.08%
656 $45,000
Q4 2023

Jan 19, 2024

SELL
$26.88 - $83.49 $564 - $1,753
-21 Reduced 5.85%
338 $28,000
Q3 2023

Oct 31, 2023

SELL
$29.46 - $36.61 $1,561 - $1,940
-53 Reduced 12.86%
359 $10,000
Q2 2023

Jul 25, 2023

BUY
$32.62 - $40.75 $3,751 - $4,686
115 Added 38.72%
412 $13,000
Q1 2023

Apr 24, 2023

BUY
$33.36 - $45.71 $1,167 - $1,599
35 Added 13.36%
297 $10,000
Q4 2022

Jan 25, 2023

BUY
$35.77 - $51.11 $393 - $562
11 Added 4.38%
262 $0
Q2 2022

Aug 04, 2022

BUY
$33.93 - $48.92 $101 - $146
3 Added 1.21%
251 $10,000
Q1 2022

Apr 19, 2022

BUY
$29.74 - $46.0 $1,100 - $1,702
37 Added 17.54%
248 $9,000
Q4 2021

Feb 01, 2022

BUY
$34.35 - $46.38 $3,331 - $4,498
97 Added 85.09%
211 $10,000
Q3 2021

Oct 15, 2021

BUY
$18.54 - $35.74 $2,113 - $4,074
114 New
114 $4,000
Q4 2019

Feb 14, 2020

SELL
$7.95 - $11.84 $3,831 - $5,706
-482 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$10.82 - $14.25 $5,215 - $6,868
482 New
482 $5,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.49B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.